AlphaMadera's AlphaVal page computes Aramark's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag ARMK as undervalued, fairly valued, or overvalued.

What is Aramark's fair value?

Fair value for ARMK is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value ARMK?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from ARMK's most recent reported fundamentals.

ARMK - Aramark

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $55.25 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 50% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Overvalued Strong

Trading 168.1% above fair value

Current Price $54.78

Bear Case $7.38 86.5% downside ($7.38 - $54.78) / $54.78 = -86.5% 5% stage 1 growth, 11% discount

Fair Value $20.44 62.7% downside ($20.44 - $54.78) / $54.78 = -62.7% 8% stage 1 growth, 11% discount

Bull Case $32.49 40.7% downside ($32.49 - $54.78) / $54.78 = -40.7% 10% stage 1 growth, 11% discount

Adjust Assumptions

DCF Stage 1 Growth Rate

7.6%

Discount Rate (WACC)

11.0%

Terminal Growth Rate

3.0%

Key Value Driver

FCF growth rate (8% base case)

Terminal Value % of EV 37%

Implied Market Multiple 47.5x

Market is pricing in (growth) 20.5% vs our 7.6% base

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $55.25 from 24 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $20.44 per share.

Warnings

ℹ Wall Street's average price target is $55.25 (from 24 analysts). Our estimate is 84% below the consensus -- consider that gap carefully.

Key Risks

P/E alone misleads — earnings depressed by growth investment
Cyclical or commodity businesses may be misclassified as platforms
Terminal value dominance suggests sensitivity to long-run assumptions